Patents

According to the estimates of the World Health Organization (WHO), the number of people with diabetes will increase from 177 million in 2000 to 300 million by 2025. It is also estimated that 9% of all deaths worldwide are due to diabetes. Although diabetes is presently not curable, intensive insulin therapy in diabetic patients can dramatically delay the onset of serious complications. It is demonstrated that tight or continuous blood glucose control can introduce substantial reductions in overall medical care costs. To date, implantable glucose sensors are all based on surface chemical ...

According to the estimates of the World Health Organization (WHO), the number of people with diabetes will increase from 177 million in 2000 to 300 million by 2025. It is also estimated that 9% of all deaths worldwide are due to diabetes. Although diabetes is presently not curable, intensive insulin therapy in diabetic patients can dramatically delay the onset of serious complications. It is demonstrated that tight or continuous blood glucose control can introduce substantial reductions in overall medical care costs. To date, implantable glucose sensors are all based on surface chemical ...

According to the estimates of the World Health Organization (WHO), the number of people with diabetes will increase from 177 million in 2000 to 300 million by 2025. It is also estimated that 9% of all deaths worldwide are due to diabetes. Although diabetes is presently not curable, intensive insulin therapy in diabetic patients can dramatically delay the onset of serious complications. It is demonstrated that tight or continuous blood glucose control can introduce substantial reductions in overall medical care costs. To date, implantable glucose sensors are all based on surface chemical ...

The present invention relates to protein binding agents specifically binding the human cation-independent mannose-6-phosphate receptor (CI-M6PR), more specifically polypeptide agents comprising an immunoglobulin single variable domain (ISVD) specifically binding CI-M6PR at nano- to picomolar affinity, fused to further protein binding agents specifically binding extracellularly-accessible protein targets, such as membrane proteins, extracellular or secreted proteins. More specifically said CI-M6PR-specific ISVD recognizes CI-M6PR N-terminal domains 1, 2 and / or 3, thereby providing for means ...

The present invention relates to protein binding agents specifically binding the human cation-independent mannose-6-phosphate receptor (CI-M6PR), more specifically polypeptide agents comprising an immunoglobulin single variable domain (ISVD) specifically binding CI-M6PR at nano- to picomolar affinity, fused to further protein binding agents specifically binding extracellularly-accessible protein targets, such as membrane proteins, extracellular or secreted proteins. More specifically said CI-M6PR-specific ISVD recognizes CI-M6PR N-terminal domains 1, 2 and / or 3, thereby providing for means ...

The present invention relates to protein binding agents specifically binding the human cation-independent mannose-6-phosphate receptor, more specifically agents comprising an immunoglobulin single variable domain (ISVD) for binding at nano- to picomolar affinity. More specifically said ISVD recognizes CI-M6PR N-terminal domains 1, 2 and / or 3, thereby providing for means and methods for internalization, lysosomal targeting and degradation of agents comprising said ISVDs. Finally the binding agents of the invention provide for use in therapeutic treatments, as diagnostics, or use in drug ...

The present invention relates to protein binding agents specifically binding the human cation-independent mannose-6-phosphate receptor (CI-M6PR), more specifically polypeptide agents comprising an immunoglobulin single variable domain (ISVD) specifically binding CI-M6PR at nano- to picomolar affinity, fused to further protein binding agents specifically binding extracellularly-accessible protein targets, such as membrane proteins, extracellular or secreted proteins. More specifically said CI-M6PR-specific ISVD recognizes CI-M6PR N-terminal domains 1, 2 and / or 3, thereby providing for means ...

The present invention relates to protein binding agents specifically binding the human cationindependent mannose-6-phosphate receptor (CI-M6PR), more specifically polypeptide agents comprising an immunoglobulin single variable domain (ISVD) specifically binding CI-M6PR at nano- to picomolar affinity, fused to further protein binding agents specifically binding extracellularly-accessible protein targets, such as membrane proteins, extracellular or secreted proteins. More specifically said CI10 M6PR-specific ISVD recognizes CI-M6PR N-terminal domains 1, 2 and / or 3, thereby providing for means ...

The present invention relates to protein binding agents specifically binding the human cation-independent mannose-6-phosphate receptor, more specifically agents comprising an immunoglobulin single variable domain (ISVD) for binding at nano- to picomolar affinity. More specifically said ISVD recognizes CI-M6PR N-terminal domains 1, 2 and / or 3, thereby providing for means and methods for internalization, lysosomal targeting and degradation of agents comprising said ISVDs. Finally the binding agents of the invention provide for use in therapeutic treatments, as diagnostics, or use in drug ...

The present invention relates to protein binding agents specifically binding the human cation- independent mannose-6-phosphate receptor, more specifically agents comprising an immunoglobulin single variable domain (ISVD) which allow internalisation upon binding to the extracellular N-terminal domains 1, 2 and / or 3 in monovalent format. More specifically said ISVD provides for means and methods for lysosomal targeting, especially when fused to further proteins such as enzymes relevant for treatment of diseases caused by a lysosomal storage phenotype or lysosomal storage diseases. Finally the ...